Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 29.77% | -18.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.77% | -18.16% | |||
| Cost of Revenue | 18.39% | -13.16% | |||
| Gross Profit | 36.98% | -21.04% | |||
| SG&A Expenses | -4.38% | -1.50% | |||
| Depreciation & Amortization | 0.00% | 44.68% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.48% | -3.85% | |||
| Operating Income | 80.88% | -106.29% | |||
| Income Before Tax | 99.93% | 47.01% | |||
| Income Tax Expenses | 10.00% | -- | |||
| Earnings from Continuing Operations | 99.73% | 46.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 99.73% | 46.92% | |||
| EBIT | 80.88% | -106.29% | |||
| EBITDA | 111.69% | -171.24% | |||
| EPS Basic | 99.85% | 49.32% | |||
| Normalized Basic EPS | 99.97% | 49.42% | |||
| EPS Diluted | 99.40% | 49.32% | |||
| Normalized Diluted EPS | 99.97% | 49.42% | |||
| Average Basic Shares Outstanding | 83.83% | 4.73% | |||
| Average Diluted Shares Outstanding | 83.83% | 4.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||